tbuckley/cabot-search huggingface dataset:
PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors.
Authors: Scott S. Tykodi, Julie R. Brahmer, Wen-Jen Hwu, Laura Q. Chow, Suzanne Louise Topalian, Patrick Hwu, Kunle Odunsi, Luis H. Camacho, John S Kauh, Henry Clement Pitot, Omid Hamid, Drew M. Pardoll, Shruti Agrawal, Susan Parker, Stacie Goldberg, Ashok Kumar Gupta, Jon Wigginton
Journal: Journal of Clinical Oncology (2012)

2510 Background: Blocking the interaction between programmed death-1 (PD-1), a co-inhibitory receptor expressed by activated T cells, and its ligand PD-L1 may enhance T-cell function. Here we describe the safety and activity from the first clinical study of BMS-936559 in patients (pts) with advanced solid tumors, further validating the importance of the PD-1/PD-L1 pathway as a target for cancer therapy. Methods: BMS-936559 was given Q2 wk IV in a 6-wk cycle at doses of 0.3−10.0 mg/kg during dose escalation and/or cohort expansion; pts could receive up to 16 cycles (48 doses). Results: As of August 1, 2011, 162 pts with melanoma (MEL, n=53), non-small-cell lung (NSCLC, n=50), colorectal (n=18), renal cell (RCC, n=17), ovarian (n=17), and pancreatic (n=7) cancer were treated. Median therapy duration was 11 wks (max 99 wks). Common related adverse events (rAEs; ≥5% pts) included fatigue, diarrhea, infusion reaction, arthralgia, rash, and pruritus. The incidence of grade 3-4 rAEs was 8.6%. AEs of special interest included hypothyroidism, hepatitis, sarcoidosis, endophthalmitis, and myasthenia gravis; there were no drug-related deaths. Clinical activity was observed in MEL, RCC, and NSCLC. Objective responses (ORs; RECIST 1.0) were observed in heavily pretreated pts. ORs were durable; among 16 pts with ORs, 7 had responses lasting ≥1 yr. Two other pts had ongoing ORs with durations of 2.3 and 8.5 mo at data lock. Several pts had prolonged stable disease. Some pts had a persistent reduction in overall tumor burden in the presence of new lesions but were not categorized as responders. In NSCLC, ORs were observed irrespective of histology. Conclusions: BMS-936559 was active and generally well tolerated in pts with NSCLC, RCC, and MEL. In conjunction with data from anti-PD-1/BMS-936558 trials, this study concurrently validates the importance of the PD-1/PD-L1 pathway for cancer immunotherapy and supports further clinical development of anti-PD-1/PD-L1 directed therapy. [Table: see text]
KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib
Authors: Ian H Gabriel, David Marin, Shahzad Ahmad, Letizia Foroni, Hugues de Lavallade, Richard E. Clark, Stephen O'Brien, Ruhena Sergeant, Dragana Milojkovic, Marco Bua, Abdullah Alsuliman, Ahmad Khoder, Kate Stringaris, Nichola Cooper, John M. Goldman, Jane F. Apperley, Katayoun Rezvani
Journal: Blood (2010)
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
Authors: A. Patnaik, L.J. Appleman, A.W. Tolcher, K.P. Papadopoulos, M. Beeram, D.W. Rasco, G.J. Weiss, J.C. Sachdev, M. Chadha, M. Fulk, S. Ejadi, J.M. Mountz, M.T. Lotze, F.G.S. Toledo, E. Chu, M. Jeffers, C. Peña, C. Xia, S. Reif, I. Genvresse, R.K. Ramanathan
Journal: Annals of Oncology (2016)

To evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of copanlisib, a phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).Phase I dose-escalation study including patients with advanced solid tumors or NHL, and a cohort of patients with type 2 diabetes mellitus. Patients received three weekly intravenous infusions of copanlisib per 28-day cycle over the dose range 0.1-1.2 mg/kg. Plasma copanlisib levels were analyzed for pharmacokinetics. Biomarker analysis included PIK3CA, KRAS, BRAF, and PTEN mutational status and PTEN immunohistochemistry. Whole-body [(18)F]-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) was carried out at baseline and following the first dose to assess early pharmacodynamic effects. Plasma glucose and insulin levels were evaluated serially.Fifty-seven patients received treatment. The MTD was 0.8 mg/kg copanlisib. The most frequent treatment-related adverse events were nausea and transient hyperglycemia. Copanlisib exposure was dose-proportional with no accumulation; peak exposure positively correlated with transient hyperglycemia post-infusion. Sixteen of 20 patients treated at the MTD had reduced (18)FDG-PET uptake; 7 (33%) had a reduction >25%. One patient achieved a complete response (CR; endometrial carcinoma exhibiting both PIK3CA and PTEN mutations and complete PTEN loss) and two had a partial response (PR; both metastatic breast cancer). Among the nine NHL patients, all six with follicular lymphoma (FL) responded (one CR and five PRs) and one patient with diffuse large B-cell lymphoma had a PR by investigator assessment; two patients with FL who achieved CR (per post hoc independent radiologic review) were on treatment >3 years.Copanlisib, dosed intermittently on days 1, 8, and 15 of a 28-day cycle, was well tolerated and the MTD was determined to be 0.8 mg/kg. Copanlisib exhibited dose-proportional pharmacokinetics and promising anti-tumor activity, particularly in patients with NHL.NCT00962611; https://clinicaltrials.gov/ct2/show/NCT00962611.
N. SUMMARY OF DISCUSSION AND COMMENTARY
Authors: E.A. Zeller
Journal: Pharmacological Reviews (1966)

Interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor Carfilzomib (CFZ) were examined in non-Hodgkin9s lymphoma models, including diffuse large B-cell (DLBCL), mantle cell (MCL) and double-hit lymphoma cells. Marked in vitro synergism was observed in multiple cell types associated with activation of cellular stress pathways (e.g., JNK1/2, ERK1/2, and p38) accompanied by increases in DNA damage (γH2A.X), G2M arrest, and the pronounced induction of mitochondrial injury and apoptosis. Combination treatment with CFZ and ricolinostat increased reactive oxygen species (ROS), while the antioxidant TBAP attenuated DNA damage, JNK activation, and cell death. Similar interactions occurred in bortezomib-resistant and double-hit DLBCL, MCL, and primary DLBCL cells, but not in normal CD34+ cells. However, ricolinostat did not potentiate inhibition of chymotryptic activity by CFZ. shRNA knock-down of JNK1 (but not MEK1/2), or pharmacologic inhibition of p38, significantly reduced CFZ/ricolinostat lethality, indicating a functional contribution of these stress pathways to apoptosis. Combined exposure to CFZ and ricolinostat also markedly down-regulated the cargo-loading protein HR23B. Moreover, HR23B knock-down significantly increased CFZ- and ricolinostat-mediated lethality, suggesting a role for this event in cell death. Finally, combined in vivo treatment with CFZ and ricolinostat was well tolerated and significantly suppressed tumor growth and increased survival in an MCL xenograft model. Collectively, these findings indicate that CFZ and ricolinostat interact synergistically in NHL cells through multiple stress-related mechanisms, and suggest that this strategy warrants further consideration in NHL.
Estimating the Risk of Radiocontrast-Associated Nephropathy
Authors: Emilee Wilhelm-Leen, Maria E. Montez-Rath, Glenn Chertow
Journal: Journal of the American Society of Nephrology (2016)

Estimates of the incidence of radiocontrast-associated nephropathy vary widely and suffer from misclassification of the cause of AKI and confounding. Using the Nationwide Inpatient Sample, we created multiple estimates of the risk of radiocontrast-associated nephropathy among adult patients hospitalized in the United States in 2009. First, we stratified patients according to the presence or absence of 12 relatively common diagnoses associated with AKI and evaluated the rate of AKI between strata. Next, we created a logistic regression model, controlling for comorbidity and acuity of illness, to estimate the risk of AKI associated with radiocontrast administration within each stratum. Finally, we performed an analysis stratified by the degree of preexisting comorbidity. In general, patients who received radiocontrast did not develop AKI at a clinically significant higher rate. Adjusted only for the complex survey design, patients to whom radiocontrast was and was not administered developed AKI at rates of 5.5% and 5.6%, respectively. After controlling for comorbidity and acuity of illness, radiocontrast administration associated with an odds ratio for AKI of 0.93 (95% confidence interval, 0.88 to 0.97). In conclusion, the risk of radiocontrast-associated nephropathy may be overstated in the literature and overestimated by clinicians. More accurate AKI risk estimates may improve clinical decision-making when attempting to balance the potential benefits of radiocontrast-enhanced imaging and the risk of AKI.
BMA invites health secretary to symposium on seven day services
Authors: Abi Rimmer
Journal: BMJ (2016)

The BMA has invited the health secretary for England, Jeremy Hunt, to take part in a symposium on seven day NHS services as it starts work to oppose the imposition of a new contract for junior doctors in England.

In a statement the association said that the meeting on the quality and consistency of healthcare delivered across the week was planned for November. It said that it would include health professionals, royal colleges, patients’ organisations, and professional associations.

The …
Disease activity and left ventricular systolic function in rheumatoid arthritis
Authors: Alessandro Giollo, Giovanni Cioffi, Federica Ognibeni, Andrea Dalbeni, Davide Gatti, Luca Idolazzi, Maurizio Rossini, Ombretta Viapiana
Journal: Annals of the Rheumatic Diseases (2016)

Disease activity and left ventricular systolic function in rheumatoid arthritisWe have read with interest the recent paper by Midtbø et al. 1 The authors evaluated 119 patients with rheumatoid arthritis (RA), and found that patients with RA active disease (Simplified Disease Activity Index (SDAI) >3.3) compared with those in remission (SDAI<3.3)had lower left ventricular (LV) systolic myocardial function, assessed by stress-corrected mid-wall shortening (scMWS) and global longitudinal strain (GLS).Data from Midtbø et al are in line with our previous work, in which we demonstrated that RA per se is a condition closely related to LV systolic dysfunction (LVSD) assessed by scMWS. 2 Furthermore, similar to other pathophysiological models (systemic hypertension, diabetes mellitus and aortic stenosis), we showed that the LVSD in patients with RA is closely associated with concentric geometry and increased LV mass (LVM), 2 which is inappropriately high in the two-third of them. 3owever, in a series of 235 patients with RA we did not find any significant relationship between RA disease activity, inflammatory markers and LVSD, 3 though in our patients with active RA the level of disease activity was significantly higher than in the Midtbø's ones (table 1).Similar findings emerged by our analysis performed on 198 patients with RA divided according to the presence/absence of combined circumferential and longitudinal LVSD, defined as the coexistence of impaired scMWS
Targeting the Wnt/β-Catenin Signaling Pathway in Multiple Myeloma: A Possible New Therapeutic Approach to Overcome Bortezomib-Resistance
Authors: Takayuki Tabayashi, Yasuyuki Takahashi, Yuta Kimura, Tatsuki Tomikawa, Morihiko Sagawa, Tomoe Nemoto, Reiko Watanabe, Michihide Tokuhira, Shigehisa Mori, Masahiro Kizaki
Journal: Blood (2014)
Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132).
Authors: D. Ross Camidge, Rebecca Suk Heist, Gregory A. Masters, Ronald J. Scheff, Alexander Starodub, Wells A. Messersmith, Aditya Bardia, Allyson J. Ocean, Leora Horn, Jordan Berlin, Pius P Maliakal, Robert M. Sharkey, Francois Wilhelm, David M. Goldenberg, Michael J. Guarino
Journal: Journal of Clinical Oncology (2016)

9011 Background: Sacituzumab govitecan (IMMU-132) is an ADC comprising SN-38, the active metabolite of the topoisomerase inhibitor, irinotecan, conjugated to an anti-Trop-2 humanized mAb. In vitro and in vivopreclinical data show that this ADC is efficacious with a high drug:antibody ratio of 7.6, and capable of delivering up to 136-fold more SN-38 than its parent drug, irinotecan, in a human cancer xenograft. The mAb and ADC are immunotherapeutic in vitro (ADCC). Trop-2 expression is increased in most epithelial cancers (>80%), including NSCLC. Therefore, the efficacy and safety of this new ADC is being examined in mNSCLC patients (pts) with > 1st line therapy. Methods: An expansion cohort from a Phase I/II clinical trial (ClinicalTrials.gov, NCT01631552) is enrolling >1st line mNSCLC pts, administering IMMU-132 on days 1 and 8 of 21-day treatment cycles. Treatment continues based on tolerance or until progression, with safety and response (RECIST 1.1) assessments made weekly and every 8 weeks, respectively. Results: Forty-five mNSCLC pts were enrolled by 11/19/15. Thirty-four are assessable [median age 62.5 yrs, 21 M/13 F, ECOG 0 (N=4)/1 (N=29)/unknown (N=1)], with a median of 3 (range, 1-7) prior lines of chemotherapy. All pts received prior treatment with platinum-based therapy. Pts were given IMMU-132 doses of 8 mg/kg (N =9) or 10 mg/kg (N =25). Tumor responses are shown in the Table. Among adverse events collected so far (n=24), grade >3 drug-related toxicities above 5% incidence are diarrhea (8%) and neutropenia (8%). No patient developed antibodies (by ELISA) to the antibody or drug. Conclusions: Objective responses and good tolerability encourage further study of IMMU-132 in mNSCLC pts with > 1st line therapy. Clinical trial information: NCT01631552.IMMU-132 Dosage Objective Response Rate (PR) , including confirmed and unconfirmed Clinical benefit (PR+ SD > 6 Months) Median Progression-Free Survival (Months) (% maturity) Median Overall Survival (Months) (% maturity) 8 mg/kg (N=9) 37% 50% 4.2 (67%) Not Reached (44%) 10 mg/kg (N=25) 29% 33% 3.8 (68%) Not Reached (8%) Both doses (N=34) 31% 35% 3.9 (68%) Not Reached (18%)
The Effects of Anti-High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Monoclonal Antibodies (mAb) Against 11q23 Positive Acute Leukemia Cells.
Authors: Allison S. Drake, Brady T. Michael, Xin Hui Wang, Sheila J.N. Sait, Justin C. Earp, William J. Jusko, Soldano Ferrone, Eunice S. Wang, Meir Wetzler
Journal: Blood (2006)
A. Long-term prognosis of diabetic patients with critical limb ischemia: a population-based cohort study. Diabetes Care 2009;32:822―827
Authors: E. Faglia, G. Clerici, J. Clerissi, L. Gabrielli, S. Losa, M. Mantero, M. Caminiti, V. Curci, A. Quarantiello, T. Luppattelli, A. Morabito
Journal: Diabetes Care (2009)
378PD Impact and predictive factor of undertreatment of analgesic drug in outpatients with cancer: a nationwide of clinical pain survey in Taiwan
Authors: C.-K. Yang, W.-C. Chou, W.-C. Shen, J.-S. Chen, K.-D. Lee, C.-J. Yen, P.-Y. Lai, Y.-Y. Shao, W.-L. Hwang, T.-J. Chiou, Y.-C. Sung, K.-M. Rau, Y.-M. Liao, C.S. Chang, M.-F. Wu, M.-Y. Lee, M.-S. Yu, T.-C. Liu, R.-K. Hsieh
Journal: Annals of Oncology (2015)
Discovery of a novel set of prostate cancer-related genes associated with the prognostically important TMPRSS2:ERG fusion gene
Authors: M. Abramovitz, R. Nam, M. Kodani, B. G. Barwick, C. Moreno, W. Tang, M. Bouzyk, A. Seth, B. Leyland-Jones
Journal: Journal of Clinical Oncology (2008)

5056 Background: Nam et al (BJC 97:1690, 2007) have recently shown that of 165 patients, the subgroup of patients who expressed the TMPRSS2:ERG fusion gene product, had a significantly higher risk of recurrence (58% at 5 yrs) than did patients who lacked the fusion protein (8% at 5 yrs) and was the single most important prognostic factor. We have used the DASL assay to expression profile 502 cancer-related genes in tumors from 145 patients from this study in order to characterize a set of additional genes that correlate with recurrence and that may shed light on novel therapeutic targets. Methods: Patients were drawn from men who underwent radical prostatectomy as the sole treatment for clinically localized PC between 1998 and 2006; at Sunnybrook Health Science Center (Toronto, ON). Most patients had a Gleason score of 7 and the primary endpoint was biochemical recurrence. Total RNA, previously prepared from frozen PC samples, was used in the DASL assay. Labeled PCR products were hybridized to a Sentrix Universal Array which was imaged using a BeadArray Reader. Data was analyzed using BeadStudio, Significance Analysis of Microarrays, Cluster, and Treeview software. Results: RT-PCR results previously classified 73 of the 145 samples as TMPRSS2:ERG gene fusion-positive and 72 as fusion-negative. Of the fusion negative only 4 samples (5.5%) showed recurrence as opposed to 28 of the 73 fusion positive samples which showed recurrence (38.4%). DASL signal intensity supports the RT-PCR results showing an average increase in ERG signal intensity of over 3-fold for samples classified as fusion-positive via RT-PCR versus those classified as fusion-negative. Associated with this bifurcation are 8 other positively regulated genes (MSF, ARHGDIB, PDGFA, HDAC1, THPO, EPHB4, CEACAM1, TRAF4) and 15 negatively regulated genes (LAF4, CD44, FGF12, EPO, IGF1, FGFR4, MAF, TGFB3, FLT1, FGF7, KDR, PTEN, PDGFRA, ETV1, IGF2) with a false discovery rate of 3%. Conclusions: Using the DASL assay on 145 patient samples we have discovered 23 regulated genes that deserve further investigation and may act as therapeutic targets. Four of these genes (CEACAM1, MSF, PDGFA and THPO) are angiogenesis-related and one that is histone acetylase-related suggest immediate therapeutic approaches. No significant financial relationships to disclose.
DNA Methylation Analysis of 807 Genes in Chronic Myeloid Leukemia and Acute Promyelocytic Leukemia.
Authors: Hyang-Min Byun, Shahrooz Eshaghian, Jia Yi Jiang, Si Ho Choi, John Soussa, Laleh Ramezani, Dan Douer, Allen S. Yang
Journal: Blood (2007)
Effect of adjuvant treatment on the circulating CK-19 mRNA-positive tumor cells in patients with early stage breast cancer
Authors: N. Xenidis, D. Mavroudis, S. Apostolaki, M. Perraki, A. Stathopoulou, E. Lianidou, V. Georgoulias
Journal: Journal of Clinical Oncology (2006)

20012 Background: To evaluate the effect of adjuvant treatment on the peripheral blood CK-19 mRNA circulating tumor cells (CTCs) in patients with early-stage breast cancer. Methods: CTCs were detected by real-time RT-PCR assay, in 119 patients with estrogen or/and progesterone receptors-positive tumors at the following time points: before the initiation and after the completion of adjuvant chemotherapy and every 3 or 6 months during the period of adjuvant tamoxifen administration. Results: Adjuvant chemotherapy failed to “eliminate” the CTCs in 17 (47%) out of 36 patients with detectable cells in pre-chemotherapy samples; in addition, adjuvant tamoxifen failed to “eliminate” the CTCs in 8 (36.4%) of 22 patients displaying detectable cells in post-chemotherapy samples. The incidence of clinical relapse was significantly (p = 0.017) higher for patients with post-chemotherapy detectable CTCs as well as for patients with persistently detectable CTCs throughout the follow-up period compared with those who did not (65.3% vs 7.3%, respectively; p &lt; 0.001). In multivariate analysis, post-chemotherapy detection of CTCs and their persistence throughout the follow-up period were significantly associated (p = 0.001 and 0.003, respectively) with early relapse. Conclusions: The detection of CK-19 mRNA + CTCs after adjuvant chemotherapy and during tamoxifen administration is an independent prognostic factor associated with unfavorable outcome. No significant financial relationships to disclose.
Antiseptics and Antibiotics for Surgical Wounds Healing by Secondary Intention
Authors: Gill Norman, Jo C. Dumville, Emma J. Crosbie
Journal: JAMA Dermatology (2016)

Do antiseptics and antibiotics benefit surgical wounds healing by secondary intention (SWHSI)?No high-quality randomized clinical trials have addressed this question. Current evidence is limited and insufficient; it is uncertain whether treating SWHSI with antiseptics or antibiotics is beneficial.
Local Delivery of PHD2 siRNA from ROS‐Degradable Scaffolds to Promote Diabetic Wound Healing
Authors: John R. Martin, Christopher E. Nelson, Mukesh K. Gupta, Fang Yu, Samantha M. Sarett, Kyle M. Hocking, Alonda C. Pollins, Lillian B. Nanney, Jeffrey M. Davidson, Scott A. Guelcher, Craig L. Duvall
Journal: Advanced Healthcare Materials (2016)

Small interfering RNA (siRNA) delivered from reactive oxygen species-degradable tissue engineering scaffolds promotes diabetic wound healing in rats. Porous poly(thioketal-urethane) scaffolds implanted in diabetic wounds locally deliver siRNA that inhibits the expression of prolyl hydroxylase domain protein 2, thereby increasing the expression of progrowth genes and increasing vasculature, proliferating cells, and tissue development in diabetic wounds.
Genomic of circulating tumor cells in metastatic breast cancer
Authors: J. M. Reuben, B. N. Lee, C. Li, K. R. Broglio, V. Valero, S. Jackson, N. T. Ueno, S. Krishnamurthy, G. N. Hortobagyi, M. Cristofanilli
Journal: Journal of Clinical Oncology (2007)

1002 Background: Metastatic breast cancer (MBC) is an incurable condition and palliative treatments are selected by considering pre-treatment prognostic and predictive factors. Recently, we reported the detection of CTCs to be predictive of prognosis and treatment efficacy and reasoned they might also be used to assess biological characteristics of the patient’s tumor to improve on treatment selection. Methods: Twenty patients with newly diagnosed MBC were enrolled in a prospective clinical trial designed to assess the baseline value of CTCs, evaluate the expression of selected genes in CTCs, and compare the expression of same biomarkers in the primary tumor (PT) and/or metastatic site (MS), as determined by standard IHC and FISH. CTCs were assessed by CellSearch, and subjected to real-time PCR (qPCR) for the expression of transcripts for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor (HER-2), notch-1, and mammaglobin (MGB) using commercial primers. Results: Sixteen of patients had =1CTCs. With respect to biomarkers of PT, 17 were ER+, 11 PR+, and 3 HER-2 amplified. Among the 15 patients with MS, the biomarkers were as follows: 9 ER+, 7 PR+, and 2 HER-2 amplified. There were significant associations between the primary and metastatic tumors with respect to the presence of ER (χ 2 = 6.516, P = 0.0107), PR (χ 2 = 5.529, P = 0.0187), and HER-2 (χ 2 = 3.938, P = 0.0472). The qPCR of CTCs detected transcripts: ER in 3 patients (15%); PR in none (0%); MGB and HER-2 in 2 (10%) and 11 patients (55%), respectively. Notch-1 transcripts were detected in 13 patients (65%). CTCs with detectable transcripts of HER-2 were more likely to co-express notch-1 transcripts (χ 2 = 4.295, P = 0.038). Of the 4 samples without detectable CTCs, one was HER-2 positive, and three had notch- 1 transcripts. Conclusions: This study demonstrated a significant concordance in biomarkers expression between the tumor cells of the primary tumors and the metastatic site. Furthermore, it suggests that CTCs differ significantly from those tumor cells with regards to the expression of hormone-receptor and HER-2 status. Thus, CTCs may represent a unique and heterogeneous cell population which phenotype and “homing” properties should be further investigated. [Table: see text]
Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors
Authors: Antonis Dagklis, Sofie Demeyer, Jolien De Bie, Enrico Radaelli, Daphnie Pauwels, Sandrine Degryse, Olga Gielen, Carmen Vicente, Roel Vandepoel, Ellen Geerdens, Anne Uyttebroeck, Nancy Boeckx, Charles E. de Bock, Jan Cools
Journal: Blood (2016)